This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.02.040v1 49/20/1993    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mocatta, T. J. Articles by Winterbourn, C. C. Search for Related Content PubMed PubMed Citation Articles by Mocatta, T. J. Articles by Winterbourn, C. C. Related Collections Related Articles

CLINICAL RESEARCH: ACUTE MYOCARDIAL INFARCTION

Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction

Tessa J. Mocatta, MSc^_*, Anna P. Pilbrow, PhD, Vicky A. Cameron, PhD, Revathy Senthilmohan, PhD, Chris M. Frampton, PhD, A. Mark Richards, MD, PhD and Christine C. Winterbourn, PhD^_*,_*

^_* Pathology
Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand

Manuscript received September 19, 2006; revised manuscript received February 9, 2007, accepted February 20, 2007.

^_* Reprint requests and correspondence: Dr. Christine C. Winterbourn, Department of Pathology, Christchurch School of Medicine and Health Sciences, P.O. Box 4345, Christchurch 8140, New Zealand. (Email: christine.winterbourn{at}chmeds.ac.nz).

Objectives: This study investigated relationships between plasma myeloperoxidase (MPO), protein oxidation markers, and clinical outcome retrospectively in patients after acute myocardial infarction (MI).

Background: Reactive oxidants are implicated in cardiovascular disease, and elevated plasma MPO is reported to predict adverse outcome in acute coronary syndromes.

Methods: Detailed demographic information, radionuclide ventriculography, neurohormone measurements, and clinical history were obtained for 512 acute MI patients at hospital admission. Plasma levels of MPO and protein carbonyls were measured in patients and 156 heart-healthy control subjects. 3-Chlorotyrosine was measured in selected patients. Patient mortality was followed for 5 years.

Results: Plasma MPO and protein carbonyl concentrations were higher in MI patients 24 h to 96 h after admission than in control subjects (medians: MPO 55 ng/ml vs. 39 ng/ml, and protein carbonyls 48 pmol/mg vs. 17 pmol/mg protein, p < 0.001 for each). Both markers were significantly correlated with each other and with cardiovascular hormone levels. Chlorotyrosine was not elevated in patients with high MPO or carbonyl levels. Above-median levels of MPO but not protein carbonyls were independently predictive of mortality (odds ratio 1.8, 95% confidence interval 1.0 to 3.0, p = 0.034). Patients with above-median MPO levels in combination with above-median plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) or below-median left ventricular ejection fraction (LVEF) had significantly greater mortality compared with other patients.

Conclusions: Myeloperoxidase and protein carbonyl levels are elevated in plasma after acute MI, apparently via independent mechanisms. High MPO is a risk factor for long-term mortality and adds prognostic value to LVEF and plasma NT-proBNP measurements.

Abbreviations and Acronyms   ANP = atrial natriuretic peptide   BNP = brain natriuretic peptide   IQR = interquartile range   LVEDV = left ventricular end-diastolic volume   LVEF = left ventricular ejection fraction   LVESV = left ventricular end-systolic volume   MI = myocardial infarction   MPO = myeloperoxidase   NT-proANP = amino-terminal pro-atrial natriuretic peptide   NT-proBNP = amino-terminal pro-brain natriuretic peptide   PTCA = percutaneous transluminal coronary angioplasty

Related Articles

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 49: A29-A30. [Full Text] [PDF]

This article has been cited by other articles:

				N. Schaub, T. Reichlin, C. Meune, R. Twerenbold, P. Haaf, W. Hochholzer, N. Niederhauser, P. Bosshard, C. Stelzig, M. Freese, et al. Markers of Plaque Instability in the Early Diagnosis and Risk Stratification of Acute Myocardial Infarction Clin. Chem., January 1, 2012; 58(1): 246 - 256. [Abstract] [Full Text] [PDF]

				A.-K. Tiden, T. Sjogren, M. Svensson, A. Bernlind, R. Senthilmohan, F. Auchere, H. Norman, P.-O. Markgren, S. Gustavsson, S. Schmidt, et al. 2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation J. Biol. Chem., October 28, 2011; 286(43): 37578 - 37589. [Abstract] [Full Text] [PDF]

				H. J. Fullerton, M. S. V. Elkind, A. J. Barkovich, C. Glaser, D. Glidden, N. K. Hills, C. Leiva-Salinas, M. Wintermark, and G. A. deVeber The Vascular Effects of Infection in Pediatric Stroke (VIPS) Study J Child Neurol, September 1, 2011; 26(9): 1101 - 1110. [Abstract] [PDF]

				S. C. Ranganathan, F. Parsons, C. Gangell, S. Brennan, S. M. Stick, P. D. Sly, and on behalf of the Australian Respiratory Early Surv Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis Thorax, May 1, 2011; 66(5): 408 - 413. [Abstract] [Full Text] [PDF]

				F. C. Meotti, G. N. L. Jameson, R. Turner, D. T. Harwood, S. Stockwell, M. D. Rees, S. R. Thomas, and A. J. Kettle Urate as a Physiological Substrate for Myeloperoxidase: IMPLICATIONS FOR HYPERURICEMIA AND INFLAMMATION J. Biol. Chem., April 15, 2011; 286(15): 12901 - 12911. [Abstract] [Full Text] [PDF]

				F. S. Apple, S. W. Smith, L. A. Pearce, K. M. Schulz, R. Ler, and M. M. Murakami Myeloperoxidase Improves Risk Stratification in Patients with Ischemia and Normal Cardiac Troponin I Concentrations Clin. Chem., April 1, 2011; 57(4): 603 - 608. [Abstract] [Full Text] [PDF]

				B. M. Scirica, M. S. Sabatine, P. Jarolim, S. A. Murphy, J. L. de Lemos, E. Braunwald, and D. A. Morrow Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial Eur. Heart J., March 2, 2011; 32(6): 697 - 705. [Abstract] [Full Text] [PDF]

				T. Naruko, A. Furukawa, K. Yunoki, R. Komatsu, M. Nakagawa, Y. Matsumura, N. Shirai, K. Sugioka, M. Takagi, T. Hozumi, et al. Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina Heart, November 1, 2010; 96(21): 1716 - 1722. [Abstract] [Full Text] [PDF]

				P. Gururajan, P. Gurumurthy, P. Nayar, S. Babu, A. Sarasabharati, D. Victor, and K. M. Cherian Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome Heart Asia, July 5, 2010; 1(1): 41 - 46. [Abstract] [Full Text] [PDF]

				V. Rudolph and S. Baldus Myeloperoxidase for Guiding Therapy for Acute Cardiac Decompensation? It's Heart to Tell Clin. Chem., June 1, 2010; 56(6): 881 - 882. [Full Text] [PDF]

				L. P. Van der Zwan, P. G. Scheffer, J. M. Dekker, C. D. A. Stehouwer, R. J. Heine, and T. Teerlink Hyperglycemia and Oxidative Stress Strengthen the Association Between Myeloperoxidase and Blood Pressure Hypertension, June 1, 2010; 55(6): 1366 - 1372. [Abstract] [Full Text] [PDF]

				S. Giovannini, G. Onder, C. Leeuwenburgh, C. Carter, E. Marzetti, A. Russo, E. Capoluongo, M. Pahor, R. Bernabei, and F. Landi Myeloperoxidase Levels and Mortality in Frail Community-Living Elderly Individuals J Gerontol A Biol Sci Med Sci, April 1, 2010; 65A(4): 369 - 376. [Abstract] [Full Text] [PDF]

				C. L. Heslop, J. J. Frohlich, and J. S. Hill Myeloperoxidase and C-Reactive Protein Have Combined Utility for Long-Term Prediction of Cardiovascular Mortality After Coronary Angiography J. Am. Coll. Cardiol., March 16, 2010; 55(11): 1102 - 1109. [Abstract] [Full Text] [PDF]

				C. B. Wright, Y. Moon, M. C. Paik, T. R. Brown, L. Rabbani, M. Yoshita, C. DeCarli, R. Sacco, and M. S. V. Elkind Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis Stroke, November 1, 2009; 40(11): 3466 - 3471. [Abstract] [Full Text] [PDF]

				N. D. Wong, H. Gransar, J. Narula, L. Shaw, J. H. Moon, R. Miranda-Peats, A. Rozanski, S. W. Hayes, L. E.J. Thomson, J. D. Friedman, et al. Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events J. Am. Coll. Cardiol. Img., September 1, 2009; 2(9): 1093 - 1099. [Abstract] [Full Text] [PDF]

				R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification? Clin. Chem., August 1, 2009; 55(8): 1462 - 1470. [Abstract] [Full Text] [PDF]

				S. J. Nicholls and S. L. Hazen Myeloperoxidase, modified lipoproteins, and atherogenesis J. Lipid Res., April 1, 2009; 50(Supplement): S346 - S351. [Abstract] [Full Text] [PDF]

				K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, M. R. Mehra, and C. R. deFilippi Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea Clin. Chem., January 1, 2009; 55(1): 59 - 67. [Abstract] [Full Text] [PDF]

				T. K. Rudolph, V. Rudolph, and S. Baldus Contribution of Myeloperoxidase to Smoking-dependent Vascular Inflammation Proceedings of the ATS, December 1, 2008; 5(8): 820 - 823. [Abstract] [Full Text] [PDF]

				G. Riccioni, V. Capra, N. D'Orazio, T. Bucciarelli, and L. A. Bazzano Leukotriene modifiers in the treatment of cardiovascular diseases J. Leukoc. Biol., December 1, 2008; 84(6): 1374 - 1378. [Abstract] [Full Text] [PDF]

				M. O. Breckwoldt, J. W. Chen, L. Stangenberg, E. Aikawa, E. Rodriguez, S. Qiu, M. A. Moskowitz, and R. Weissleder Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase PNAS, November 25, 2008; 105(47): 18584 - 18589. [Abstract] [Full Text] [PDF]

				T. A. Dawson, D. Li, T. Woodward, Z. Barber, L. Wang, and D. J. Paterson Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H990 - H998. [Abstract] [Full Text] [PDF]

				J. Shih, S. A. Datwyler, S. C. Hsu, M. S. Matias, D. P. Pacenti, C. Lueders, C. Mueller, O. Danne, and M. Mockel Effect of Collection Tube Type and Preanalytical Handling on Myeloperoxidase Concentrations Clin. Chem., June 1, 2008; 54(6): 1076 - 1079. [Abstract] [Full Text] [PDF]

				D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18 Eur. Heart J., May 1, 2008; 29(9): 1096 - 1102. [Abstract] [Full Text] [PDF]

				M. Nahrendorf, D. Sosnovik, J. W. Chen, P. Panizzi, J.-L. Figueiredo, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury Circulation, March 4, 2008; 117(9): 1153 - 1160. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the Year in JACC 2007 J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF]

				H. L. Gornik Peripheral arterial disease enters the biomarker era. Does risk stratification tell us something that we don't already know? Eur. Heart J., January 2, 2008; 29(2): 150 - 152. [Full Text] [PDF]

				D. A. Morrow Appraisal of Myeloperoxidase for Evaluation of Patients With Suspected Acute Coronary Syndromes J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2001 - 2002. [Full Text] [PDF]